Otsuka Pharmaceutical Co., Ltd.

Trial and FDA signals

• Drug approval + hiring FDA novel approval for SIMTRIYO (NDA 218145, Jul 24, 2026; +1 other approval); 95 manufacturing/quality or commercial roles open. FDA NDA 218145 (Jul 24, 2026)
  Evidence (2 events)

  • Jul 24, 2026 · FDA NDA 218145
    openFDA drugsfda: application_number=NDA218145; sponsor_name='OTSUKA PHARMACEUTICAL CO LTD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260724; submission_class_code=TYPE 1; brand_name=['SIMTRIYO']
  • Nov 25, 2025 · FDA BLA 761434
    openFDA drugsfda: application_number=BLA761434; sponsor_name='OTSUKA PHARM CO LTD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251125; submission_class_code=TYPE 1; brand_name=['VOYXACT']

Job counts as of Oct 18, 2026. All trial and FDA signals